The prescription medication Pradaxa, made by Boehringer Ingelheim, has been linked to more than 250 deaths in the previous two years. Primarily prescribed as an anti-coagulant drug, Pradaxa can cause internal bleeding in patients. Elevated risk of internal bleeding was discovered when the medication underwent clinical trials. Pradaxa is often prescribed for persons at a higher risk of developing a stroke because it prevents blood from clotting.
In October of 2010, The United States Food and Drug Administration (FDA) approved clot fighting drug Pradaxa as a method of preventing strokes and blood clots in patients diagnosed with atrial fibrillation, a syndrome responsible for irregular heart rhythms. Recently, however, Pradaxa has been the subject of numerous lawsuits over internal bleeding side effects that question Pradaxa's safety.
Boehringer Ingelheim is a family-owned company that is also a subsidiary of the larger organization, C.H. Boehringer Sohn AG & Ko. KG. It was started in 1885 in the German town of Ingelheim am Rhein by Albert Boehringer, and it has remained there ever since. The company’s 145 branches are currently employing 42,000 people. The principle tasks of this company are the research and development and manufacturing and marketing of medications for human as well as animal consumption. Recently, the company has been the subject of numerous lawsuits over internal bleeding side effects caused by their drug Pradaxa.